Baek Wook-Young, Lee Sung-Min, Lee Sang-Won, Son In-Ok, Choi Sangdun, Suh Chang-Hee
Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
Department of Molecular Science and Technology, Ajou University, Suwon, Korea.
J Rheum Dis. 2021 Jul 1;28(3):133-142. doi: 10.4078/jrd.2021.28.3.133.
Systemic lupus erythematosus (SLE) is a common chronic autoimmune inflammatory disease According to recent studies, signaling through Toll-like receptor (TLR) protein, which promotes the production of inflammatory cytokines, leads to the development of SLE TLR-inhibitory peptide 1 (TIP1) has been newly identified for the treatment of autoimmune diseases.
The effect of TIP1 was analyzed in an SLE mouse model (MRL/) The mice in the control treatment group (n=5) were administered an intravenous injection of phosphate-buffered saline twice weekly, whereas the mice in the TIP1 treatment group (n=6) were administered an intravenous injection of TIP1 (1 nmol/g) twice weekly MRL/ mice (n=5) were selected as normal controls The mice were injected for 4 weeks between 14 and 18 weeks of age, followed by assays of their spleen, kidneys, lymph nodes, serum, and urine.
The antinuclear antibody and inflammatory cytokine (interferon-α) in the serum as well as levels of albumin in the urine of the mice in the TIP1 treatment group had decreased when compared to those of mice in the control treatment group Kidney inflammation in mice in the TIP1 treatment group was alleviated The mRNA expression levels of TLR7- or TLR9-related downstream signaling molecules also decreased in all organs of the mice in the TIP1 treatment group.
Intravenous treatment with TIP1 reduces symptoms and markers of inflammation in MRL/ mice Hence, TIP1 is a promising medication for the treatment of SLE.
系统性红斑狼疮（SLE）是一种常见的慢性自身免疫性炎症性疾病。根据最近的研究，通过Toll样受体（TLR）蛋白发出的信号促进炎症细胞因子的产生，导致SLE的发展。TLR抑制肽1（TIP1）是新发现的用于治疗自身免疫性疾病的药物。
在SLE小鼠模型（MRL/lpr）中分析TIP1的作用。对照治疗组（n = 5）的小鼠每周两次静脉注射磷酸盐缓冲盐水，而TIP1治疗组（n = 6）的小鼠每周两次静脉注射TIP1（1 nmol/g）。选择MRL/lpr小鼠（n = 5）作为正常对照。在14至18周龄之间给小鼠注射4周，随后对其脾脏、肾脏、淋巴结、血清和尿液进行检测。
与对照治疗组小鼠相比，TIP1治疗组小鼠血清中的抗核抗体和炎症细胞因子（干扰素-α）以及尿液中的白蛋白水平均降低。TIP1治疗组小鼠的肾脏炎症得到缓解。TIP1治疗组小鼠所有器官中TLR7或TLR9相关下游信号分子的mRNA表达水平也降低。
TIP1静脉注射治疗可减轻MRL/lpr小鼠的炎症症状和标志物。因此，TIP1是一种有前途的治疗SLE的药物。
